Mainz Biomed B.V. (MYNZ) は上場企業です ヘルスケア セクターの Medical - Diagnostics & Research 業界で事業展開. 本社所在地は Mainz, ドイツ. 現CEOは Guido Baechler.
MYNZ を有する IPO日 2021-11-05, 19 名の正社員, に上場 NASDAQ Capital Marke, 時価総額 $2.86M.
Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.
